<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Ecopetrol Sa</title>
	<atom:link href="http://www.stockbloghub.com/tag/ecopetrol-sa/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AZN) AstraZeneca Drug Cleared by the European Commission</title>
		<link>http://www.stockbloghub.com/2011/12/08/azn-astrazeneca-drug-cleared-by-the-european-commission/87920</link>
		<comments>http://www.stockbloghub.com/2011/12/08/azn-astrazeneca-drug-cleared-by-the-european-commission/87920#comments</comments>
		<pubDate>Thu, 08 Dec 2011 19:01:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87920</guid>
		<description><![CDATA[AstraZeneca (AZN) and its partner Bristol-Myers Squibb (BMY) announced recently that Komboglyze has been approved by the European Commission (EC) in European Union (EU). Komboglyze is a combination of Onglyza (saxagliptin), a DPP-4 inhibitor and metformin, a generic drug for type II diabetes. AstraZeneca has co-developed Onglyza with Bristol-Myers. The EC cleared Komboglyze as an adjunct to diet and exercise to improve glycemic control in adults suffering from type II diabetes. Komboglyze is indicated for patients who show inadequate response to the maximum tolerated dose of metformin alone or those already being treated with the combination of Onglyza and metformin as separate tablets. Komboglyze is expected to provide single pill dosing convenience to patients currently taking Onglyza and metformin seperately. We remind investors that Komboglyze was approved by the US ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/08/azn-astrazeneca-drug-cleared-by-the-european-commission/87920/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Reports Solid Quarter</title>
		<link>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092</link>
		<comments>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092#comments</comments>
		<pubDate>Wed, 03 Aug 2011 19:53:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80092</guid>
		<description><![CDATA[Bristol-Myers Squibb Company’s (BMY) second quarter 2011 earnings (excluding special items) of $0.56 per share surpassed the Zacks Consensus Estimate by $0.01and the year-ago earnings by $0.02. Higher revenues boosted earnings in the reported quarter. On a reported basis (including special items), Bristol-Myers’ earnings in the quarter decreased 2% to $0.52 per share. The healthcare reform enacted in 2010 negatively impacted earnings in the reported quarter by $0.03. Net sales in the reported quarter climbed 14% to $5.4 billion. Foreign exchange positively impacted sales in the quarter by 4%. Revenues also surpassed the Zacks Consensus Estimate of $5.0 billion, driven by the impressive showing of Bristol-Myers’ lead drugs including blood thinner Plavix. US net sales in the quarter climbed 15% to $3.6 billion. Sales in international markets increased 13% to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma Quarterly Earnings Report Misses Due to Higher Expenses</title>
		<link>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406</link>
		<comments>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406#comments</comments>
		<pubDate>Wed, 03 Aug 2011 15:34:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80406</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) posted second quarter fiscal 2011 earnings of 36 cents per share, missing the Zacks Consensus Estimate by 3 cents and the year-ago figure by a penny. Despite higher revenues, earnings bore the brunt of increased operating expenses. Revenues Higher sales from Cinryze boosted the quarterly revenues from $109.0 million in the year-ago quarter to $128.8 million. However, revenues fell shy of the Zacks Consensus Estimate of $131.0 million. Cinryze sales increased 55.1% to $62.5 million during the reported quarter, while Vancocin sales came in at $65.2 million, reflecting a slide of 4.7%. The increase in Cinryze sales was due to higher patient demand. On the other hand, Vancocin sales were negatively impacted by declining volume, partly offset by price rise. Other Details Research and development (R&#38;D) expenses ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EC) Roche Holdings Gets FDA Panel View on Avastin</title>
		<link>http://www.stockbloghub.com/2011/06/30/ec-roche-holdings-gets-fda-panel-view-on-avastin/78019</link>
		<comments>http://www.stockbloghub.com/2011/06/30/ec-roche-holdings-gets-fda-panel-view-on-avastin/78019#comments</comments>
		<pubDate>Thu, 30 Jun 2011 21:16:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Oil & Gas Drilling & Exploration]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78019</guid>
		<description><![CDATA[Roche Holdings Ltd. (RHHBY) recently announced that the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recommended that the agency should withdraw its approval for the use of Avastin (bevacizumab) in combination with paclitaxel in previously untreated (first-line) HER2-negative metastatic breast cancer. The FDA Commissioner will take a final call on this matter. However, the recommendation is not expected to impact other indications of the drug. Avastin is approved in the US for treating other types of cancer and in other countries for treating metastatic breast cancer. Recently, the company also announced that the European Commission (EC) has approved Avastin to be used in combination with Xeloda (capecitabine) as a first-line treatment for metastatic breast cancer in women for whom treatment with other chemotherapies is considered ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/30/ec-roche-holdings-gets-fda-panel-view-on-avastin/78019/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CHMP) ViroPharma&#8217;s Epilepsy Drug Recommended</title>
		<link>http://www.stockbloghub.com/2011/06/28/chmp-viropharmas-epilepsy-drug-recommended/77702</link>
		<comments>http://www.stockbloghub.com/2011/06/28/chmp-viropharmas-epilepsy-drug-recommended/77702#comments</comments>
		<pubDate>Tue, 28 Jun 2011 20:02:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Business Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77702</guid>
		<description><![CDATA[The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently gave the go ahead to ViroPharma Inc.’s (VPHM) Buccolam (midazolam, oromucosal solution). The company is seeking approval for Buccolam to be used as a treatment for prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years. The European Commission’s (EC) decision on ViroPharma’s Pediatric Use Marketing Authorization (PUMA) for Buccolam is expected by the fourth quarter of 2011, which will also make the candidate the first product to gain approval under the centralized PUMA procedure. PUMA is a new type of centralized marketing authorization procedure for medicines that are developed specifically for children and may already be approved for other indications or routes of administration in adults. ViroPharma’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/28/chmp-viropharmas-epilepsy-drug-recommended/77702/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire&#8217;s Firazyr Earns FDA Panel Backing</title>
		<link>http://www.stockbloghub.com/2011/06/26/shpgy-shires-firazyr-earns-fda-panel-backing/77456</link>
		<comments>http://www.stockbloghub.com/2011/06/26/shpgy-shires-firazyr-earns-fda-panel-backing/77456#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:48:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77456</guid>
		<description><![CDATA[Recently, the Pulmonary-Allergy Drugs Advisory Committee of the US Food and Drug Administration (FDA) issued a positive opinion and recommended the US approval of Shire’s (SHPGY) Firazyr (icatibant). Shire is looking to get Firazyr approved in the US for treating patients (aged 18 years and above) suffering from acute attacks of hereditary angioedema (HAE). HAE is a rare genetic disease characterized by acute swelling of the hands, feet, face and larynx. The FDA panel was convinced of Firazyr’s safety and effectiveness based on data from three double-blind, randomized late-stage studies (FAST-1, FAST-2, and FAST-3). Twelve of the 13 members of the panel recommended the approval of the drug for the indication. Moreover, 11 of the 13 members (one member voted against the motion while the other panel member abstained from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/shpgy-shires-firazyr-earns-fda-panel-backing/77456/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb and Pfizer Report Positive Data on Blood Thinner Apixaban Drug</title>
		<link>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318</link>
		<comments>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:18:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77318</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging top line data from a late-stage study (ARISTOTLE: n=18,201) which evaluated their blood thinner apixaban in patients suffering from an erratic heartbeat. This cardiac rhythm disorder is referred to as atrial fibrillation (AF). Apixaban will be marketed under the trade name Eliquis in the EU. The same trade name has been proposed in the US and other countries. Top-line results from the double-blind, multicenter study revealed that Eliquis was non-inferior to the standard therapy warfarin with respect to the combined outcome of stroke and systemic embolism. Data further revealed that Eliquis was superior to warfarin with respect to effectiveness and major bleeding. Bristol-Myers and Pfizer intend to seek approval from the US Food and Drug Administration (FDA) and also ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec and Partner Elan Announce EU Label Update for Tysabri</title>
		<link>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127</link>
		<comments>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127#comments</comments>
		<pubDate>Wed, 22 Jun 2011 19:16:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77127</guid>
		<description><![CDATA[Recently, Biogen Idec, Inc. (BIIB) and partner Elan Corporation (ELN) announced that the European Commission (EC) has approved an update to the label for their multiple sclerosis (MS) drug Tysabri (natalizumab) in the European Union (EU). The updated label includes anti-JC Virus antibody status as an additional factor that could help stratify the risk of progressive multifocal leukoencephalopathy (PML) occurring in patients treated with Tysabri. The EC’s decision for the label update does not surprise us as in April 2011 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) had backed the inclusion of the additional risk in the Tysabri label. The updated label in the EU will provide patients (treated with Tysabri) as well as doctors additional assistance in identifying the risk of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma&#8217;s HAE Drug Gets EU Nod</title>
		<link>http://www.stockbloghub.com/2011/06/16/vphm-viropharmas-hae-drug-gets-eu-nod/76542</link>
		<comments>http://www.stockbloghub.com/2011/06/16/vphm-viropharmas-hae-drug-gets-eu-nod/76542#comments</comments>
		<pubDate>Thu, 16 Jun 2011 15:20:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76542</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) recently announced that the European Commission (EC) granted Centralized Marketing Authorization to Cinryze for the treatment of hereditary angioedema (HAE). The drug is indicated for the treatment of pre-procedure prevention of angioedema attacks in adults and adolescents with HAE, and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of HAE, who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment. The EC’s approval of Cinryze does not come as a surprise, as in March the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended it. We note that in May, ViroPharma had entered into a global licensing deal with Halozyme Therapeutics, Inc. (HALO), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/vphm-viropharmas-hae-drug-gets-eu-nod/76542/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Compan Gets Good News</title>
		<link>http://www.stockbloghub.com/2011/06/15/bmy-bristol-myers-squibb-compan-gets-good-news/74752</link>
		<comments>http://www.stockbloghub.com/2011/06/15/bmy-bristol-myers-squibb-compan-gets-good-news/74752#comments</comments>
		<pubDate>Wed, 15 Jun 2011 16:49:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74752</guid>
		<description><![CDATA[Bristol-Myers Squibb Company (BMY) received a boost when its blood-thinner Eliquis (apixaban) was cleared by the European Commission (EC) in 27 nations of the European Union (EU) for preventing venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery. The approval by the EC is the first approval for Eliquis, a new oral direct factor Xa inhibitor. Bristol-Myers has co-developed the drug with Pfizer (PFE). The approval was based on ADVANCE-2 and ADVANCE-3 studies which revealed that the drug was statistically superior to 40 mg once-daily Lovenox (enoxaparin) of Sanofi-Aventis (SNY) without increase in bleeding rates. The decision of the EC to approve Eliquis does not surprise us since the drug had won a positive recommendation from the Committee for Medicinal Products for Human Use ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/15/bmy-bristol-myers-squibb-compan-gets-good-news/74752/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EC) Ecopetrol S.A. &#8211; Exploratory Oil and Gas Production Up 14%</title>
		<link>http://www.stockbloghub.com/2009/12/18/ec-ecopetrol-s-a-exploratory-oil-and-gas-production-up-14/23185</link>
		<comments>http://www.stockbloghub.com/2009/12/18/ec-ecopetrol-s-a-exploratory-oil-and-gas-production-up-14/23185#comments</comments>
		<pubDate>Sat, 19 Dec 2009 00:01:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Oil & Gas Drilling & Exploration]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23185</guid>
		<description><![CDATA[Ecopetrol S.A. (EC) estimates are climbing and the company recently laid out its 2010 investment plan, that includes an 11% increase. Company Description Ecopetrol is a Colombian petroleum company. The company extracts, collects, treats, stores and pumps oil and gas. $7 Billion Investment On Dec 11 Ecopetrol said it will increase its investment plan by 11%, to $6.93 billion in 2010. The vast majority of the money will go into Columbia. About 65% will go toward exploration and production. Production Up 14% Ecopetrol reported third-quarter results on Oct 21 that included a 13% rise in total production. During the month of September the company started 12 new exploratory wells. Sales volume rose almost 18% on higher production and purchases of hydrocarbons. Earnings per share were 2 cents, however there are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/18/ec-ecopetrol-s-a-exploratory-oil-and-gas-production-up-14/23185/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical Earns Orphan Status From FDA</title>
		<link>http://www.stockbloghub.com/2009/12/02/bmrn-biomarin-pharmaceutical-earns-orphan-status-from-fda/21751</link>
		<comments>http://www.stockbloghub.com/2009/12/02/bmrn-biomarin-pharmaceutical-earns-orphan-status-from-fda/21751#comments</comments>
		<pubDate>Wed, 02 Dec 2009 20:18:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21751</guid>
		<description><![CDATA[Recently, BioMarin Pharmaceutical Inc. (BMRN) announced that the U.S. Food and Drug Administration (FDA) granted orphan drug status to its candidate 3,4-diaminopyridine amifampridine phosphate (3,4-DAP), for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). As a reminder, BioMarin acquired the privately held Huxley Pharmaceuticals Inc. last month which possessed rights to a proprietary form of 3, 4-diaminopyridine amifampridine phosphate for LEMS treatment. In October 2009, the Committee for Medicinal Products for Human Use of the European Medicines Evaluations Agency gave a positive opinion and recommended the approval of amifampridine phosphate for LEMS. The European Commission (EC) is expected to deliver its decision regarding the approvability of the candidate in late 2009 or early 2010.BioMarin intends to launch the drug in Europe in the first quarter of 2010 and is looking ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/02/bmrn-biomarin-pharmaceutical-earns-orphan-status-from-fda/21751/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AEG) Investing in ADRs: The Most Powerful Way to Reduce Market Risk</title>
		<link>http://www.stockbloghub.com/2009/09/14/aeg-investing-in-adrs-the-most-powerful-way-to-reduce-market-risk/15076</link>
		<comments>http://www.stockbloghub.com/2009/09/14/aeg-investing-in-adrs-the-most-powerful-way-to-reduce-market-risk/15076#comments</comments>
		<pubDate>Mon, 14 Sep 2009 17:47:06 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Life Insurance]]></category>
		<category><![CDATA[Acorn International Inc.]]></category>
		<category><![CDATA[AEG]]></category>
		<category><![CDATA[Aegon N V Adr]]></category>
		<category><![CDATA[ARA]]></category>
		<category><![CDATA[Aracruz Celulose S.A.]]></category>
		<category><![CDATA[ATV]]></category>
		<category><![CDATA[Banco Macro S.A.]]></category>
		<category><![CDATA[Berkshire Hathaway Incorporated Class B]]></category>
		<category><![CDATA[BMA]]></category>
		<category><![CDATA[BRKB]]></category>
		<category><![CDATA[Copa Holdings SA]]></category>
		<category><![CDATA[CPA]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[HMIN]]></category>
		<category><![CDATA[Home Inns & Hotels Management]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15076</guid>
		<description><![CDATA[by Dr. Scott Brown, Advisory Panelist It’s official: You can reduce your investment risk simply by chucking darts at a list of stocks, then buying them. That’s if you believe a Nobel economist, of course. His crude “experiment” was the start of “modern portfolio theory” decades ago. The downside, however, was that with a reduction of risk came a dampening of profits. So scratch that idea. How about this? A startling study in the late 1970s showed that owning a portfolio of large U.S. companies with international divisions drops your risk 10% below a domestic stock portfolio. Much better. But that wasn’t the eye-popper… The study also found that owning stocks in international companies cuts your risk in half… Take that, “efficiency” theorists! Yet the stuffy professors still tried to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/14/aeg-investing-in-adrs-the-most-powerful-way-to-reduce-market-risk/15076/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

